source
- UCB commits $2 billion to Candid's T cell engager program for autoimmune diseasesUCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions. The deal reflects U…
- Celcuity reports positive Phase 3 data for gedatolisib, bolstering broader approval prospectsCelcuity announced new data from an ongoing Phase 3 trial of its experimental breast cancer drug gedatolisib. The data showed that two- and three-drug combinations that included gedatolisib delaye…